Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1437-1445

  Naslund, M J ^a   Gilsenan, A W ^b   Midkiff, K D ^b   Bown, A ^c   Wolford, E T ^c   Wang, J ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGITAL RECTAL EXAMINATION; DISEASE CLASSIFICATION; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE;

AGED; CROSS-SECTIONAL STUDIES; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; PHYSICIAN-PATIENT RELATIONS; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATISM; QUALITY OF LIFE; QUESTIONNAIRES; URINATION DISORDERS;

EID: 34547797395     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01508.x     Document Type: Article

References (23)

1. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005 173 : 1256 61.
2. Roehrborn CG, McConnell JD, Barry MJ et al. AUA Guideline on the Management of Benign Prostatic Hyperplasia: Diagnosis and Treatment Recommendations [AUA Web site], 2003. http://www.auanet.org/guidelines/ main_reports/bph_management/chapt_1_appendix.pdf (accessed February 2007).
3. Roehrborn CG, McConnell JD, Lieber M. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with benign prostatic hyperplasia. Urology 1999 53 : 473 80.
4. Roehrborn CG, Boyle P, Nickel JC. PSA is a significant predictor of objective parameters in men at risk for BPH progression. J Urol 2003 169 : A1362.
5. McConnell JD, Roehrborn CG, Slawin KM et al. Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients. J Urol 2003 169 : A1287.
6. McConnell JD, Roehrborn CG, Bautista OM et al. and the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98.
7. Kaplan SA, McConnell JD, Roehrborn CG et al. and the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006 175 : 217 20, 220 1.
8. Roehrborn CG, Boyle P, Gould AL et al. Serum prostate-specific antigen as a predictor of prostate volume in men with a benign prostatic hyperplasia. Adult Urol 1999 53 : 581 9.
9. Bosch J, Bohnen AM, Groeneveld F. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50-78 years: the Krimpen Study. Eur Urol 2004 46 : 753 9.
10. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993 150 : 85 9.
11. Wei JT, Schottenfeld D, Cooper K et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 2001 165 : 1521 5.
12. Trueman P, Hood SC, Nayak USL et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on QOL in a community-based survey of men in the UK. BJU Int 1999 83 : 410 5.
13. Barry MJ, Fowler FJ, O'Leary MP et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992 148 : 1549 57.
14. Barry MJ, Fowler FJ, O'Leary MP et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995 33 : AS145 55.
15. Blanker MH, Groeneveld FP, Prins A et al. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status. BJU Int 2000 85 : 665 71.
16. Panser LA, Chute CG, Guess HA et al. The natural history of prostatism: the effects of non-response bias. Int J Epidemiol 1994 23 : 1198 205.
17. National Center for Health Statistics. NAMCS Description [CDC Web site], 2003. http://www.cdc.gov/nchs/about/major/ahcd/namcsdes.htm (accessed March 2006).
18. Roehrborn CG, McConnell JD. Benign prostatic hyperplasia etiology, pathophysiology, epidemiology and natural history. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology, Chapter 86. Philadelphia, USA : Saunders, Elsevier, 2007 : 2727 65.
19. Roehrborn CG, Girman CJ, Rhodes T et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997 49 : 548 57.
20. Roehrborn CG, Sech S, Montoya J et al. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology 2001 57 : 1087 92.
21. Badia X, Rodriguez F, Carballido J et al. and the ESECI-98 Group. Influence of sociodemographic and health status variables on the American Urological Association symptom scores in patients with lower urinary tract symptoms. Urology 2001 57 : 71 7.
22. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998 338 : 557 63.
23. Black L, Naslund MJ, Gilbert TD Jr. et al. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006 12 (Suppl. 4 S99 110.